Page 5 - Heart Failure Guidelines
P. 5
Pediatric Heart Failure Guidelines
Neuromuscular Disorder Associated Cardiomyopathy ..............................................................25
Additional Evaluation for Patient with Neuromuscular Disorder associated Cardiomyopathy .25
Introduction ...............................................................................................................................25
Initial Evaluation ........................................................................................................................25
Ongoing Management ...............................................................................................................25
Dose escalation plan (outpatient monitoring) .........................................................................26
Imaging .....................................................................................................................................27
Arrhythmia Screening ................................................................................................................27
Advanced Therapies .................................................................................................................27
Myocarditis ................................................................................................................................28
Additional Evaluation for possible Myocarditis .......................................................................28
Medical Management Myocarditis .........................................................................................28
Immunotherapy Management Myocarditis .............................................................................28
Follow-up Schedule for Myocarditis .......................................................................................29
Medication Doses .....................................................................................................................30
Anticoagulation Schedules ........................................................................................................32
Updated 5/17/2018 page 5
